
Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients with moderate-to-severe palmoplantar psoriasis achieved clear or almost clear skin on their palms and … Read the full press release